Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Immunotherapy was reported in the treatment of psoriasis. Treatment of resistant psoriasis may be difficult and cyclosporine can induce some remission.

The investigators hypothesized that the combined use of live attenuated varicella vaccine as an adjuvant therapy to low dose cyclosporine in the treatment of severe resistant psoriasis can give positive responses.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cairo University
• Treatments: Vaccines

Criteria

Inclusion Criteria:

• Severe psoriasis: At least 30% of body involved) according to the rule of nine.

• Resistance to conventional therapy (PUVA, methotrexate, retinoids):

(Maximum PASI 50% improvement while on treatment for a duration not less than 6 months).

• Immunologically competent individuals with

• Seropositive for the varicella antibodies

Exclusion Criteria:

• Any contraindication to live attenuated varicella vaccine

• Any contraindication to cyclosporine